Discover 1,670 paid clinical trials in Princeton, New Jersey. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,670
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
for
Moderate-to-Severe Atopic Dermatitis
Location: Robbinsville NJ, The Bronx NY, Columbus OH, Savannah GA,
Sponsor: Nektar Therapeutics
Sex: All
Age: 12+
Code: NCT07711418
Phase 3, Recruiting
Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
for
Relapsed Classic Hodgkin Lymphoma
Location: Hackensack NJ, Boston MA, Chicago IL, Nashville TN,
Sponsor: City of Hope Medical Center
Sex: All
Age: 18+
Code: NCT04561206
Phase 2, Recruiting
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors
for
Thymoma, Thymic Carcinoma
Location: Hackensack NJ, Washington D.C. DC, Chicago IL,
Sponsor: Georgetown University
Sex: All
Age: 18+
Code: NCT06248515
Phase 2, Recruiting
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
for
Small Cell Lung Cancer
Location: Hackensack NJ, Boston MA, Buffalo NY, Chicago IL,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06780137
Phase 1, Phase 2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)
for
Solid Tumors
Location: Hackensack NJ, New Haven CT, Los Angeles CA
Sponsor: Boehringer Ingelheim
Sex: All
Age: 18+
Code: NCT05471856
Phase 1, Recruiting
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
for
Multiple Myeloma
Location: Hackensack NJ, New Haven CT, Toronto, Halifax,
Sponsor: Celgene
Sex: All
Age: 18+
Code: NCT06988488
Phase 1, Phase 2, Recruiting
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
Predictive Value of Lung Ultrasound for Respiratory Decompensation in Late Preterm Neonates
for
Pre-Term, Respiratory Distress of Newborn, Premature
Location: Hackensack NJ
Sponsor: Hackensack Meridian Health
Sex: All
Age: 0
Code: NCT07216053
Recruiting
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
for
Head and Neck Squamous Cell Carcinoma,
Location: Hackensack NJ, Richmond VA, Pittsburgh PA,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06980038
Phase 2, Recruiting
A Study in People With Advanced Cancer to Test How Well Different Doses of BI 3819026 Are Tolerated When Taken Alone and Together With Ezabenlimab
for
Advanced Solid Cancer, Metastatic Solid Cancer
Location: Hackensack NJ, New Haven CT, Nashville TN
Sponsor: Boehringer Ingelheim
Sex: All
Age: 18+
Code: NCT07607678
Phase 1, Recruiting
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
for
Moderate-to-Severe Atopic Dermatitis
Location: New York NY, Clifton NJ, Wilmington NC, Auburn Hills MI,
Sponsor: Nektar Therapeutics
Sex: All
Age: 12+
Code: NCT07690371
Phase 3, Recruiting
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.